Evidence map›Paper›PMID 31139178›Full record

ReviewFrontiers in immunology2019

Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?

David P Funda, Lenka Palová-Jelínková, Jaroslav Goliáš, Zuzana Kroulíková, Alena Fajstová, Tomáš Hudcovic, Radek Špíšek

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Clinical Use ofFrontiers in immunology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

David P FundaInstitute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
Lenka Palová-JelínkováSOTIO a s., Prague, Czechia.
Jaroslav GoliášInstitute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
Zuzana KroulíkováInstitute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
Alena FajstováInstitute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
Tomáš HudcovicInstitute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
Radek ŠpíšekSOTIO a s., Prague, Czechia.
Czech Academy of Sciences, Institute of Microbiology · CZCharles University · CZSotio (Czechia) · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however, T1D displays some unique features. In addition, unlike in several disease-induced animal models of autoimmune diseases, the prevalent animal model for T1D, the NOD mouse, develops diabetes spontaneously. This review compares evidence of various tolDCs approaches obtained from animal (mainly NOD) models of T1D with a focus on parameters of this cell-based therapy such as protocols of tolDC preparation, antigen-specific

Indexed as

AnimalsDendritic CellsDiabetes Mellitus, Type 1Disease Models, AnimalImmune ToleranceMiceMice, Inbred NODanimal modelscell therapyNOD mouseprotocol optimizationtolerogenic dendritic cellstype 1 diabetes

Identifiers

PMID31139178
PMCPMC6527741
OpenAlexW2946472496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.